metformin has been researched along with Protein Aggregation, Pathological in 2 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Protein Aggregation, Pathological: A biochemical phenomenon in which misfolded proteins aggregate either intra- or extracellularly. Triggered by factors such as MUTATION; POST-TRANSLATIONAL MODIFICATIONS, and environmental stress, it is generally associated with ALZHEIMER DISEASE; PARKINSON DISEASE; HUNTINGTON DISEASE; and TYPE 2 DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Huntington disease is a neurodegenerative condition for which there is no cure to date." | 5.51 | Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease. ( Cañada-Martínez, AJ; García-Gimeno, MA; Millán, JM; Sanchis, A; Sanz, P; Sequedo, MD; Vázquez-Manrique, RP, 2019) |
| "Huntington disease is a neurodegenerative condition for which there is no cure to date." | 1.51 | Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease. ( Cañada-Martínez, AJ; García-Gimeno, MA; Millán, JM; Sanchis, A; Sanz, P; Sequedo, MD; Vázquez-Manrique, RP, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gómez-Escribano, AP | 1 |
| Bono-Yagüe, J | 1 |
| García-Gimeno, MA | 2 |
| Sequedo, MD | 2 |
| Hervás, D | 1 |
| Fornés-Ferrer, V | 1 |
| Torres-Sánchez, SC | 1 |
| Millán, JM | 2 |
| Sanz, P | 2 |
| Vázquez-Manrique, RP | 2 |
| Sanchis, A | 1 |
| Cañada-Martínez, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Metformin, an Activator of AMPK, on Cognitive Measures of Progression in Huntington's Disease Patients"[NCT04826692] | Phase 3 | 60 participants (Anticipated) | Interventional | 2021-12-10 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for metformin and Protein Aggregation, Pathological
| Article | Year |
|---|---|
Synergistic activation of AMPK prevents from polyglutamine-induced toxicity in Caenorhabditis elegans.
Topics: AMP-Activated Protein Kinases; Animals; Animals, Genetically Modified; Autophagy; Caenorhabditis ele | 2020 |
Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease.
Topics: AMP-Activated Protein Kinases; Animals; Brain; Caenorhabditis elegans; Disease Models, Animal; Human | 2019 |